Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Alkermes Q3 Earnings Fall, Revenue Rises; Reiterates 2026 Revenue Guidance

Alkermes Q3 Earnings Fall, Revenue Rises; Reiterates 2026 Revenue Guidance

MT newswireMT newswire2026/11/03 11:43
07:43 AM EST, 11/03/2026 (MT Newswires) -- Alkermes (ALKS) reported Q3 earnings Tuesday of $0.09 per diluted share, down from $0.49 a year earlier. Analysts polled by FactSet expected a loss of $0.08. Total revenue for the quarter ended Sept. 30 was $480.1 million, up from $394.2 million a year earlier. Analysts polled by FactSet expected $463.5 million. For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion. Analysts polled by FactSet expected $1.82 billion. Alkermes shares were up 3.9% in premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss